Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 621

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Asialoglycoprotein receptor mediated hepatocyte targeting — Strategies and applications

D'Souza, Anisha A., Devarajan, Padma V.·2015·Journal of Controlled Release
DOI 10.1016/j.jconrel.2015.02.022
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2015.02.022

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 238

  1. Mazzanti, 2008, Hepatocellular carcinoma: epidemiology and clinical aspects, Mol. Asp. Med., 29, 130, 10.1016/j.mam.2007.09.008 · DOI
  2. Lavanchy, 2004, Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures, J. Viral Hepat., 11, 97, 10.1046/j.1365-2893.2003.00487.x · DOI · Paper page
  3. Kawakami, 2014, Glycosylation-mediated targeting of carriers, J. Control. Release, 190, 542, 10.1016/j.jconrel.2014.06.001 · DOI
  4. Grewal, 2010, Chapter thirteen — the Ashwell–Morell receptor, 223, 10.1016/S0076-6879(10)79013-3 · DOI
  5. Stockert, 1995, The asialoglycoprotein receptor: relationships between structure, function, and expression, Physiol. Rev., 75, 591, 10.1152/physrev.1995.75.3.591 · DOI · Paper page
  6. Harris, 2012, ASGR1 and ASGR2, the genes that encode the asialoglycoprotein receptor (Ashwell receptor), are expressed in peripheral blood monocytes and show interindividual differences in transcript profile, Mol. Biol. Int., 2012, 10, 10.1155/2012/283974 · DOI
  7. Dodeur, 1982, Effects of streptozotocin-induced diabetes mellitus on the binding and uptake of asialoorosomucoid by isolated hepatocytes from rats, Eur. J. Biochem., 123, 383, 10.1111/j.1432-1033.1982.tb19780.x · doi:10.1111/j.1432-1033.1982.tb19780.x
  8. Li, 2008, Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development, Curr. Drug Deliv., 5, 299, 10.2174/156720108785915069 · DOI
  9. Onizuka, 2012, NMR study of ligand release from asialoglycoprotein receptor under solution conditions in early endosomes, FEBS J., 279, 2645, 10.1111/j.1742-4658.2012.08643.x · DOI
  10. D'Souza, 2013, Comparative in silico–in vivo evaluation of ASGP-R ligands for hepatic targeting of curcumin Gantrez nanoparticles, AAPS J., 15, 696, 10.1208/s12248-013-9474-6 · DOI
  11. Wu, 2002, Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications, Front. Biosci., 7, d717
  12. Ramadugu, 2010, In silico prediction of the 3D structure of trimeric asialoglycoprotein receptor bound to triantennary oligosaccharide, J. Am. Chem. Soc., 132, 9087, 10.1021/ja1021766 · DOI
  13. McAbee, 2000, Lactoferrin binding to the rat asialoglycoprotein receptor requires the receptor's lectin properties, Biochem. J., 348, 113, 10.1042/bj3480113 · doi:10.1042/bj3480113
  14. Tanabe, 1979, Subcellular membrane topology and turnover of a rat hepatic binding protein specific for asialoglycoproteins, J. Biol. Chem., 254, 1038, 10.1016/S0021-9258(17)34164-9 · DOI · Paper page
  15. Varga, 2000, Receptor-mediated targeting of gene delivery vectors: insights from molecular mechanisms for improved vehicle design, Biotechnol. Bioeng., 70, 593, 10.1002/1097-0290(20001220)70:6<593::AID-BIT1>3.0.CO;2-N · doi:10.1002/1097-0290(20001220)70:6<593::aid-bit1>3.0.co;2-n
  16. Schwartz, 1984, Recycling of the asialoglycoprotein receptor and the effect of lysosomotropic amines in hepatoma cells, J. Cell Biol., 98, 732, 10.1083/jcb.98.2.732 · DOI · Paper page
  17. Schwartz, 1982, Kinetics of internalization and recycling of the asialoglycoprotein receptor in a hepatoma cell line, J. Biol. Chem., 257, 4230, 10.1016/S0021-9258(18)34710-0 · DOI · Paper page
  18. Warren, 1981, Turnover of the surface proteins and the receptor for serum asialoglycoproteins in primary cultures of rat hepatocytes, J. Biol. Chem., 256, 1346, 10.1016/S0021-9258(19)69971-0 · DOI
  19. Wang, 2013, N-acetylgalactosamine functionalized mixed micellar nanoparticles for targeted delivery of siRNA to liver, J. Control. Release, 166, 106, 10.1016/j.jconrel.2012.12.017 · DOI
  20. Kolatkar, 1998, Mechanism of N-acetylgalactosamine binding to a C-type animal lectin carbohydrate-recognition domain, J. Biol. Chem., 273, 19502, 10.1074/jbc.273.31.19502 · DOI
  21. Ruiz, 1996, Differential ligand binding by two subunits of the rat liver asialoglycoprotein receptor, Glycobiology, 6, 551, 10.1093/glycob/6.5.551 · DOI
  22. Mukthavaram, 2009, Cationic glycolipids with cyclic and open galactose head groups for the selective targeting of genes to mouse liver, Biomaterials, 30, 2369, 10.1016/j.biomaterials.2008.12.074 · DOI
  23. Franssen, 1993, Hepatic and intrahepatic targeting of an anti-inflammatory agent with human serum albumin and neoglycoproteins as carrier molecules, Biochem. Pharmacol., 45, 1215, 10.1016/0006-2952(93)90273-Y · DOI
  24. Kawakami, 2002, Glycosylated cationic liposomes for cell-selective gene delivery, Crit. Rev. Ther. Drug Carrier Syst., 19, 171, 10.1615/CritRevTherDrugCarrierSyst.v19.i2.30 · doi:10.1615/critrevtherdrugcarriersyst.v19.i2.30
  25. Stokmaier, 2009, Design, synthesis and evaluation of monovalent ligands for the asialoglycoprotein receptor, Bioorg. Med. Chem., 17, 7254, 10.1016/j.bmc.2009.08.049 · DOI
  26. Nishikawa, 2005, Development of cell-specific targeting systems for drugs and genes, Biol. Pharm. Bull., 28, 195, 10.1248/bpb.28.195 · DOI
  27. Managit, 2003, Targeted and sustained drug delivery using PEGylated galactosylated liposomes, Int. J. Pharm., 266, 77, 10.1016/S0378-5173(03)00383-1 · DOI
  28. Wong, 1987, Synthesis of D-galactosamine derivatives and binding studies using isolated rat hepatocytes, Carbohydr. Res., 170, 27, 10.1016/0008-6215(87)85003-6 · doi:10.1016/0008-6215(87)85003-6
  29. Staud, 1999, Liver uptake and hepato-biliary transfer of galactosylated proteins in rats are determined by the extent of galactosylation, Biochim. Biophys. Acta, 1427, 183, 10.1016/S0304-4165(99)00031-8 · DOI
  30. Nishikawa, 1998, Targeted delivery of plasmid DNA to hepatocytes in vivo: optimization of the pharmacokinetics of plasmid DNA/galactosylated poly(ʟ-lysine) complexes by controlling their physicochemical properties, J. Pharmacol. Exp. Ther., 287, 408, 10.1016/S0022-3565(24)37804-8 · DOI
  31. Hashida, 2001, Cell-specific delivery of genes with glycosylated carriers, Adv. Drug Deliv. Rev., 52, 187, 10.1016/S0169-409X(01)00209-5 · DOI · Paper page
  32. Lee, 2011, New and more efficient multivalent glyco-ligands for asialoglycoprotein receptor of mammalian hepatocytes, Bioorg. Med. Chem., 19, 2494, 10.1016/j.bmc.2011.03.027 · doi:10.1016/j.bmc.2011.03.027
  33. Biessen, 1995, Synthesis of cluster galactosides with high affinity for the hepatic asialoglycoprotein receptor, J. Med. Chem., 38, 1538, 10.1021/jm00009a014 · DOI
  34. Rensen, 2001, Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting, Adv. Drug Deliv. Rev., 47, 251, 10.1016/S0169-409X(01)00109-0 · DOI · Paper page
  35. Connolly, 1982, Binding and endocytosis of cluster glycosides by rabbit hepatocytes. Evidence for a short-circuit pathway that does not lead to degradation, J. Biol. Chem., 257, 939, 10.1016/S0021-9258(19)68290-6 · DOI · Paper page
  36. Westerlind, 2004, Ligands of the asialoglycoprotein receptor for targeted gene delivery, part 1: synthesis of and binding studies with biotinylated cluster glycosides containing N-acetylgalactosamine, Glycoconj. J., 21, 227, 10.1023/B:GLYC.0000045095.86867.c0 · DOI
  37. Singh, 2003, Targeted gene delivery into HepG2 cells using complexes containing DNA, cationized asialoorosomucoid and activated cationic liposomes, J. Control. Release, 92, 383, 10.1016/S0168-3659(03)00360-2 · DOI
  38. Rice, 1990, Defined geometry of binding between triantennary glycopeptide and the asialoglycoprotein receptor of rat heptocytes, J. Biol. Chem., 265, 18429, 10.1016/S0021-9258(17)44770-3 · DOI
  39. Lee, 1992, Biochemistry of carbohydrate–protein interaction, FASEB J., 6, 3193, 10.1096/fasebj.6.13.1397841 · DOI · Paper page
  40. Joziasse, 2000, a3-Galactosylated glycoproteins can bind to the hepatic asialoglycoprotein receptor, Eur. J. Biochem., 267, 6501, 10.1046/j.1432-1327.2000.01747.x · DOI
  41. Saunier, 2003, Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes, J. Virol., 77, 546, 10.1128/JVI.77.1.546-559.2003 · DOI
  42. Sliedregt, 1999, Design and synthesis of novel amphiphilic dendritic galactosides for selective targeting of liposomes to the hepatic asialoglycoprotein receptor, J. Med. Chem., 42, 609, 10.1021/jm981078h · DOI
  43. Managit, 2005, Effect of galactose density on asialoglycoprotein receptor-mediated uptake of galactosylated liposomes, J. Pharm. Sci., 94, 2266, 10.1002/jps.20443 · DOI
  44. McAbee, 1999, Copper and zinc ions differentially block asialoglycoprotein receptor-mediated endocytosis in isolated rat hepatocytes, J. Biol. Chem., 274, 14750, 10.1074/jbc.274.21.14750 · doi:10.1074/jbc.274.21.14750
  45. Geffen, 1991, Phorbol ester-induced redistribution of the ASGP receptor is independent of receptor phosphorylation, FEBS Lett., 305, 209, 10.1016/0014-5793(92)80669-8 · DOI
  46. Kim, 2006, Asialoglycoprotein-receptor-targeted hepatocyte imaging using 99mTc galactosylated chitosan, Nucl. Med. Biol., 33, 529, 10.1016/j.nucmedbio.2006.03.005 · doi:10.1016/j.nucmedbio.2006.03.005
  47. Debanne, 1982, Receptor-rich intracellular membrane vesicles transporting asialotransferrin and insulin in liver, Nature, 298, 398, 10.1038/298398a0 · doi:10.1038/298398a0
  48. Fiume, 1997, Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor, J. Viral Hepat., 4, 363, 10.1046/j.1365-2893.1997.00067.x · DOI
  49. McKee, 1994, Preparation of asialoorosomucoid-polylysine conjugates, Bioconjug. Chem., 5, 306, 10.1021/bc00028a004 · DOI
  50. Arangoa, 2003, Increased receptor-mediated gene delivery to the liver by protamine-enhanced-asialofetuin-lipoplexes, Gene Ther., 10, 5, 10.1038/sj.gt.3301840 · DOI
  51. Fiume, 1997, Hepatotropic conjugate of adenine arabinoside monophosphate with lactosaminated poly-ʟ-lysine. Synthesis of the carrier and pharmacological properties of the conjugate, J. Hepatol., 26, 253, 10.1016/S0168-8278(97)80038-4 · doi:10.1016/s0168-8278(97)80038-4
  52. Regoeczi, 1978, Elimination of asialofetuin and asialoorosomucoid by the intact rat. Quantitative aspects of the hepatic clearance mechanism, Biochim. Biophys. Acta, 541, 372, 10.1016/0304-4165(78)90196-4 · doi:10.1016/0304-4165(78)90196-4
  53. Mishra, 2013, Efficient hepatic delivery of drugs: novel strategies and their significance, Biomed. Res. Int., 2013, 382184, 10.1155/2013/382184 · DOI
  54. Tanaka, 2004, Cellular disposition of arabinogalactan in primary cultured rat hepatocytes, Eur. J. Pharm. Sci., 22, 435, 10.1016/j.ejps.2004.04.014 · DOI
  55. Kaneo, 2000, Pharmacokinetics and biodisposition of fluorescein-labeled arabinogalactan in rats, Int. J. Pharm., 201, 59, 10.1016/S0378-5173(00)00405-1 · doi:10.1016/s0378-5173(00)00405-1
  56. Kelly, 1999, Larch arabinogalactan: clinical relevance of a novel immune-enhancing polysaccharide, Altern. Med. Rev., 4, 96
  57. Beuth, 1987, Inhibition of liver metastasis in mice by blocking hepatocyte lectins with arabinogalactan infusions and d-galactose, J. Cancer Res. Clin. Oncol., 113, 51, 10.1007/BF00389966 · DOI
  58. Bertoldo, 2004, Cloning, sequencing, and characterization of a heat- and alkali-stable type I pullulanase from Anaerobranca gottschalkii, Appl. Environ. Microbiol., 70, 3407, 10.1128/AEM.70.6.3407-3416.2004 · doi:10.1128/aem.70.6.3407-3416.2004
  59. Gupta, 2004, In vitro cytotoxicity studies of hydrogel pullulan nanoparticles prepared by AOT/N-hexane micellar system, J. Pharm. Pharm. Sci., 7, 38
  60. Tanaka, 2005, Uptake of pullulan in cultured rat liver parenchymal cells, Biol. Pharm. Bull., 28, 560, 10.1248/bpb.28.560 · doi:10.1248/bpb.28.560
  61. Kaneo, 2001, Evidence for receptor-mediated hepatic uptake of pullulan in rats, J. Control. Release, 70, 365, 10.1016/S0168-3659(00)00368-0 · DOI · Paper page
  62. San Juan, 2007, Cationized pullulan 3D matrices as new materials for gene transfer, J. Biomed. Mater. Res. A, 82, 354, 10.1002/jbm.a.31062 · doi:10.1002/jbm.a.31062
  63. Yim, 2011, The performance of gadolinium diethylene triamine pentaacetate-pullulan hepatocyte-specific T1 contrast agent for MRI, Biomaterials, 32, 5187, 10.1016/j.biomaterials.2011.03.069 · doi:10.1016/j.biomaterials.2011.03.069
  64. Jo, 2007, Expression profile of plasmid DNA by spermine derivatives of pullulan with different extents of spermine introduced, J. Control. Release, 118, 389, 10.1016/j.jconrel.2007.01.005 · DOI
  65. Yu, 2014, In vitro and in vivo evaluation of pectin-based nanoparticles for hepatocellular carcinoma drug chemotherapy, Mol. Pharm., 11, 638, 10.1021/mp400412c · DOI
  66. Maitani, 2001, Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as a liver targeting carrier in HepG2 cells, J. Control. Release, 75, 381, 10.1016/S0168-3659(01)00411-4 · DOI
  67. Shimizu, 1997, Formulation of liposomes with a soybean-derived sterylglucoside mixture and cholesterol for liver targeting, Biol. Pharm. Bull., 20, 881, 10.1248/bpb.20.881 · doi:10.1248/bpb.20.881
  68. Ghiamkazemi, 2010, Synthesis, and characterization, and evaluation of cellular effects of the FOL-PEG-g-PEI-GAL nanoparticles as a potential non-viral vector for gene delivery, J. Nanomater., 10
  69. Meng, 2005, Immobilization of lactobionic acid on polyurethane films and their interaction with hepatocytes, Macromol. Res., 13, 257, 10.1007/BF03219061 · doi:10.1007/bf03219061
  70. Spanjer, 1983, Targeting of lactosylceramide-containing liposomes to hepatocytes in vivo, Biochim. Biophys. Acta, 734, 40, 10.1016/0005-2736(83)90072-X · DOI
  71. Baenziger, 1980, Human hepatic lectin-physiochemical properties and specificity, J. Biol. Chem., 255, 7, 10.1016/S0021-9258(19)85538-2 · DOI · Paper page
  72. Rotundo, 1998, Circulating cellular fibronectin may be a natural ligand for the hepatic asialoglycoprotein receptor: possible pathway for fibronectin deposition and turnover in the rat liver, Hepatology, 28, 475, 10.1002/hep.510280227 · DOI
  73. Akamatsu, 1998, Disposition characteristics of glycosylated poly(amino acids) as liver cell-specific drug carrier, J. Drug Target., 6, 229, 10.3109/10611869808997897 · DOI
  74. Hirabayashi, 1996, Development and pharmacokinetics of galactosylated poly-ʟ-glutamic acid as a biodegradable carrier for liver-specific drug delivery, Pharm. Res., 13, 880, 10.1023/A:1016053128569 · DOI
  75. Liang, 2005, Preparation of nanoparticles composed of poly(γ-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cells, J. Control. Release, 105, 213, 10.1016/j.jconrel.2005.03.021 · DOI
  76. Qin, 2011, Galactosylated N-2-hydroxypropyl methacrylamide-b-N-3-guanidinopropyl methacrylamide block copolymers as hepatocyte-targeting gene carriers, Bioconjug. Chem., 22, 1503, 10.1021/bc100525y · doi:10.1021/bc100525y
  77. Jiang, 2008, Galactosylated poly(ethylene glycol)-chitosan-graft-polyethylenimine as a gene carrier for hepatocyte-targeting, J. Control. Release, 131, 150, 10.1016/j.jconrel.2008.07.029 · DOI
  78. Park, 2000, Galactosylated chitosan-graft-dextran as hepatocyte-targeting DNA carrier, J. Control. Release, 69, 97, 10.1016/S0168-3659(00)00298-4 · DOI · Paper page
  79. Kato, 2001, Biological characteristics of lactosaminated N-succinyl-chitosan as a liver-specific drug carrier in mice, J. Control. Release, 70, 295, 10.1016/S0168-3659(00)00356-4 · DOI
  80. Cook, 2005, Galactosylated polyethylenimine-graft-poly(vinyl pyrrolidone) as a hepatocyte-targeting gene carrier, J. Control. Release, 105, 151, 10.1016/j.jconrel.2005.03.011 · DOI
  81. Kunath, 2003, Galactose-PEI–DNA complexes for targeted gene delivery: degree of substitution affects complex size and transfection efficiency, J. Control. Release, 88, 159, 10.1016/S0168-3659(02)00458-3 · DOI · Paper page
  82. Sonoke, 2011, Galactose-modified cationic liposomes as a liver-targeting delivery system for small interfering RNA, Biol. Pharm. Bull., 34, 1338, 10.1248/bpb.34.1338 · DOI
  83. Zhang, 2013, Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma, J. Control. Release, 168, 251, 10.1016/j.jconrel.2013.03.020 · DOI
  84. Shigeta, 2007, Novel histidine-conjugated galactosylated cationic liposomes for efficient hepatocyte-selective gene transfer in human hepatoma HepG2 cells, J. Control. Release, 118, 262, 10.1016/j.jconrel.2006.12.019 · doi:10.1016/j.jconrel.2006.12.019
  85. Wang, 2006, Synthesis of a novel galactosylated lipid and its application to the hepatocyte-selective targeting of liposomal doxorubicin, Eur. J. Pharm. Biopharm., 62, 32, 10.1016/j.ejpb.2005.07.004 · DOI
  86. Ding, 2013, Efficacious hepatoma-targeted nanomedicine self-assembled from galactopeptide and doxorubicin driven by two-stage physical interactions, J. Control. Release, 169, 193, 10.1016/j.jconrel.2012.12.006 · DOI
  87. Schindl, 2006, The adaptive response of the reticuloendothelial system to major liver resection in humans, Ann. Surg., 243, 507, 10.1097/01.sla.0000205826.62911.a7 · DOI
  88. Hillaireau, 2009, Nanocarriers' entry into the cell: relevance to drug delivery, Cell. Mol. Life Sci., 66, 2873, 10.1007/s00018-009-0053-z · DOI · Paper page
  89. Wu, 1987, Receptor-mediated in vitro gene transformation by a soluble DNA carrier system, J. Biol. Chem., 262, 4429, 10.1016/S0021-9258(18)61209-8 · DOI · Paper page
  90. Fiume, 1979, Enhanced inhibition of virus DNA synthesis in hepatocytes by trifluorothymidine coupled to asialofetuin, FEBS Lett., 103, 47, 10.1016/0014-5793(79)81247-8 · DOI
  91. Fiume, 1987, Conjugates of ara-AMP with lactosaminated albumin: a study on their immunogenicity in mouse and rat, Cancer Drug Deliv., 4, 145, 10.1089/cdd.1987.4.145 · DOI
  92. Merwin, 1994, Targeted delivery of DNA using YEE(GalNAcAH)3, a synthetic glycopeptide ligand for the asialoglycoprotein receptor, Bioconjug. Chem., 5, 612, 10.1021/bc00030a017 · DOI
  93. Suginoshita, 2002, Liver targeting of human interferon-beta with pullulan based on metal coordination, J. Control. Release, 83, 75, 10.1016/S0168-3659(02)00197-9 · doi:10.1016/s0168-3659(02)00197-9
  94. Akamatsu, 1999, Development of a hepatocyte-specific prostaglandin E(1) polymeric prodrug and its potential for preventing carbon tetrachloride-induced fulminant hepatitis in mice, J. Pharmacol. Exp. Ther., 290, 1242, 10.1016/S0022-3565(24)35028-1 · DOI
  95. Di Stefano, 1997, Ribavirin conjugated with lactosaminated poly-ʟ-lysine: selective delivery to the liver and increased antiviral activity in mice with viral hepatitis, Biochem. Pharmacol., 54, 357
  96. Ma, 2012, Inhibition of hepatitis B virus and induction of hepatoma cell apoptosis by ASGPR-directed delivery of shRNAs, PLoS One, e46096, 10.1371/journal.pone.0046096 · DOI
  97. Di Stefano, 2000, Enhanced liver blood concentrations of adenine arabinoside accomplished by lactosaminated poly-ʟ-lysine coupling: implications for regional chemotherapy of hepatic micrometastases, Biochem. Pharmacol., 59, 301, 10.1016/S0006-2952(99)00327-5 · doi:10.1016/s0006-2952(99)00327-5
  98. Peng, 2007, Inhibition of hepatocarcinoma by systemic delivery of apoptin gene via the hepatic asialoglycoprotein receptor, Cancer Gene Ther., 14, 66, 10.1038/sj.cgt.7700985 · doi:10.1038/sj.cgt.7700985
  99. Hu, 2012, Study on galactose-poly(ethylene glycol)-poly(L-lysine) as novel gene vector for targeting hepatocytes in vitro, J. Biomater. Sci. Polym. Ed., 23, 677, 10.1163/092050611X558297 · DOI
  100. Sagara, 2002, A new synthesis of galactose-poly(ethylene glycol)-polyethylenimine for gene delivery to hepatocytes, J. Control. Release, 79, 271, 10.1016/S0168-3659(01)00555-7 · DOI
  101. Ong, 2013, Galactose-functionalized cationic polycarbonate diblock copolymer for targeted gene delivery to hepatocytes, Macromol. Rapid Commun., 34, 1714, 10.1002/marc.201300538 · DOI
  102. Kim, 2004, Galactosylated chitosan/DNA nanoparticles prepared using water-soluble chitosan as a gene carrier, Biomaterials, 25, 3783, 10.1016/j.biomaterials.2003.10.063 · DOI · Paper page
  103. Yang, 2014, A biocleavable pullulan-based vector via ATRP for liver cell-targeting gene delivery, Biomaterials, 35, 3873, 10.1016/j.biomaterials.2014.01.036 · DOI
  104. Maruyama, 2004, Novel receptor-mediated gene delivery system comprising plasmid/protamine/sugar-containing polyanion ternary complex, Biomaterials, 25, 3267, 10.1016/j.biomaterials.2003.10.004 · DOI
  105. Hopewel, 2001, Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent, Hum. Exp. Toxicol., 20, 461, 10.1191/096032701682693017 · DOI
  106. Seymour, 2002, Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin, J. Clin. Oncol., 20, 1668, 10.1200/JCO.2002.20.6.1668 · doi:10.1200/jco.2002.20.6.1668
  107. Julyan, 1999, Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine, J. Control. Release, 57, 281, 10.1016/S0168-3659(98)00124-2 · DOI · Paper page
  108. Liu, 2010, Photodynamic therapy of fullerene modified with pullulan on hepatoma cells, J. Drug Target., 18, 602, 10.3109/10611861003599479 · DOI
  109. Han, 1999, Enhanced hepatocyte uptake and liver targeting of methotrexate using galactosylated albumin as a carrier, Int. J. Pharm., 188, 39, 10.1016/S0378-5173(99)00206-9 · DOI
  110. Ishihara, 2011, Nuclear localization and antisense effect of PNA internalized by ASGP-R-mediated endocytosis with protein/DNA conjugates, J. Control. Release, 155, 34, 10.1016/j.jconrel.2010.10.014 · DOI
  111. Hashida, 1998, Targeted delivery of plasmid DNA complexed with galactosylated poly(ʟ-lysine), J. Control. Release, 53, 301, 10.1016/S0168-3659(97)00263-0 · DOI
  112. Aoyama, 2002, Liver targeting of plasmid DNA by pullulan conjugation based on metal coordination, J. Control. Release, 83, 287, 10.1016/S0168-3659(02)00201-8 · DOI
  113. Zhu, 2010, Targeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugation, Bioconjug. Chem., 21, 2119, 10.1021/bc100346n · DOI
  114. Tomiya, 2013, Liver-targeting of primaquine-(poly-gamma-glutamic acid) and its degradation in rat hepatocytes, Bioorg. Med. Chem., 21, 5275, 10.1016/j.bmc.2013.06.028 · doi:10.1016/j.bmc.2013.06.028
  115. Wilson, 1992, Hepatocyte-directed gene transfer in vivo leads to transient improvement of hypercholesterolemia in low density lipoprotein receptor-deficient rabbits, J. Biol. Chem., 267, 963, 10.1016/S0021-9258(18)48379-2 · DOI · Paper page
  116. Iyanagi, 1998, Biochemical and molecular aspects of genetic disorders of bilirubin metabolism, Biochim. Biophys. Acta, 1407, 173, 10.1016/S0925-4439(98)00044-1 · DOI
  117. Hashida, 1997, Targeted delivery of drugs and proteins to the liver via receptor-mediated endocytosis, J. Control. Release, 46, 129, 10.1016/S0168-3659(96)01577-5 · DOI
  118. Muro, 2012, Challenges in design and characterization of ligand-targeted drug delivery systems, J. Control. Release, 164, 125, 10.1016/j.jconrel.2012.05.052 · DOI · Paper page
  119. Singh, 2008, Recent trends in targeted anticancer prodrug and conjugate design, Curr. Med. Chem., 15, 1802, 10.2174/092986708785132997 · DOI · Paper page
  120. Fiume, 1984, Selective penetration and pharmacological activity of lactosaminated albumin conjugates of adenine arabinoside 5-monophosphate (ara-AMP) in mouse liver, Gut, 25, 1392, 10.1136/gut.25.12.1392 · doi:10.1136/gut.25.12.1392
  121. Sunderland, 2006, Targeted nanoparticles for detecting and treating cancer, Drug Dev. Res., 67, 70, 10.1002/ddr.20069 · DOI · Paper page
  122. Arora, 2012, Nanocarriers enhance doxorubicin uptake in drug-resistant ovarian cancer cells, Cancer Res., 72, 769, 10.1158/0008-5472.CAN-11-2890 · DOI
  123. Rensen, 2001, Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo, J. Biol. Chem., 276, 37577, 10.1074/jbc.M101786200 · DOI · Paper page
  124. Popielarski, 2005, A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 1. Synthesis and characterization, Bioconjug. Chem., 16, 1063, 10.1021/bc050113d · DOI
  125. Schlepper-Schafer, 1986, Endocytosis via galactose receptors in vivo. Ligand size directs uptake by hepatocytes and/or liver macrophages, Exp. Cell Res., 165, 494
  126. Biessen, 1994, Cholesterol derivative of a new triantennary cluster galactoside directs low- and high-density lipoproteins to the parenchymal liver cell, Biochem. J., 302, 283, 10.1042/bj3020283 · DOI
  127. Kuiper, 1994, Characterization of the interaction of galactose-exposing particles with rat Kupffer cells, Biochem. J., 299, 285, 10.1042/bj2990285 · DOI
  128. Shimizu, 1998, Targeting of soybean-derived sterylglucoside liposomes to liver tumors in rat and mouse models, Biol. Pharm. Bull., 21, 741, 10.1248/bpb.21.741 · DOI
  129. Wang, 2006, Delivery of different length poly(ʟ-lysine)-conjugated ODN to HepG2 cells using N-stearyllactobionamide-modified liposomes and their enhanced cellular biological effects, Int. J. Pharm., 311, 82, 10.1016/j.ijpharm.2005.12.014 · DOI
  130. Biessen, 1994, Specific targeting of the antiviral drug 5-iodo 2′-deoxyuridine to the parenchymal liver cell using lactosylated poly-ʟ-lysine, J. Hepatol., 21, 806, 10.1016/S0168-8278(94)80243-2 · DOI
  131. Soenen, 2011, The labeling of cationic iron oxide nanoparticle-resistant hepatocellular carcinoma cells using targeted magnetoliposomes, Biomaterials, 32, 1748, 10.1016/j.biomaterials.2010.11.005 · DOI
  132. Longmuir, 2006, Effective targeting of liposomes to liver and hepatocytes in vivo by incorporation of a Plasmodium amino acid sequence, Pharm. Res., 23, 759, 10.1007/s11095-006-9609-x · DOI
  133. Shimada, 1997, Biodistribution of liposomes containing synthetic galactose-terminated diacylglyceryl-poly(ethyleneglycol)s, Biochim. Biophys. Acta Biomembr., 1326, 329, 10.1016/S0005-2736(97)00036-9 · DOI
  134. Murao, 2002, Targeting efficiency of galactosylated liposomes to hepatocytes in vivo: effect of lipid composition, Pharm. Res., 19, 1808, 10.1023/A:1021433206081 · DOI
  135. Naicker, 2014, PEGylated galactosylated cationic liposomes for hepatocytic gene delivery, Colloids Surf. B: Biointerfaces, 122, 482, 10.1016/j.colsurfb.2014.07.010 · doi:10.1016/j.colsurfb.2014.07.010
  136. Nishikawa, 1992, Pharmacokinetics of receptor-mediated hepatic uptake of glycosylated albumin in mice, Int. J. Pharm., 85, 75, 10.1016/0378-5173(92)90136-P · DOI
  137. Weigel, 1980, Characterization of the asialoglycoprotein receptor on isolated rat hepatocytes, J. Biol. Chem., 255, 6111, 10.1016/S0021-9258(18)43708-8 · doi:10.1016/s0021-9258(18)43708-8
  138. Dragsten, 1987, Drug delivery using vesicles targeted to the hepatic asialoglycoprotein receptor, Biochim. Biophys. Acta, 926, 270, 10.1016/0304-4165(87)90213-3 · DOI
  139. Kawakami, 2001, Novel galactosylated liposomes for hepatocyte-selective targeting of lipophilic drugs, J. Pharm. Sci., 90, 105, 10.1002/1520-6017(200102)90:2<105::AID-JPS1>3.0.CO;2-1 · doi:10.1002/1520-6017(200102)90:2<105::aid-jps1>3.0.co;2-1
  140. Kawakami, 1998, Asialoglycoprotein receptor-mediated gene transfer using novel galactosylated cationic liposomes, Biochem. Biophys. Res. Commun., 252, 78, 10.1006/bbrc.1998.9602 · DOI · Paper page
  141. Hara, 1996, Effects of fusogenic and DNA-binding amphiphilic compounds on the receptor-mediated gene transfer into hepatic cells by asialofetuin-labeled liposomes, Biochim. Biophys. Acta, 1278, 51, 10.1016/0005-2736(95)00205-7 · doi:10.1016/0005-2736(95)00205-7
  142. Zhang, 2007, Mechanisms of co-modified liver-targeting liposomes as gene delivery carriers based on cellular uptake and antigens inhibition effect, J. Control. Release, 117, 281, 10.1016/j.jconrel.2006.11.006 · DOI
  143. Tep, 2009, Formulation and evaluation of ATP-containing liposomes including lactosylated ASGPr ligand, J. Liposome Res., 19, 287, 10.3109/08982100902838682 · doi:10.3109/08982100902838682
  144. Hai, 2010, Synthesis of multivalent galactosides as targeting ligand for gene delivery, Synth. Commun., 40, 1802, 10.1080/00397910903161827 · doi:10.1080/00397910903161827
  145. Narainpersad, 2012, Novel neo glycolipid: formulation into pegylated cationic liposomes and targeting of DNA lipoplexes to the hepatocyte-derived cell line HepG2, Nucleosides Nucleotides Nucleic Acids, 31, 206, 10.1080/15257770.2011.649331 · doi:10.1080/15257770.2011.649331
  146. Zhou, 2012, Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma, Int. J. Nanomedicine, 7, 5465
  147. Terada, 2006, Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting, J. Control. Release, 111, 333, 10.1016/j.jconrel.2005.12.023 · DOI · Paper page
  148. Sun, 2005, Targeted gene delivery to hepatoma cells using galactosylated liposome-polycation-DNA complexes (LPD), J. Drug Target., 13, 121, 10.1080/10611860400024714 · doi:10.1080/10611860400024714
  149. Cho, 2009, Suppression of hepatitis B virus-derived human hepatocellular carcinoma by NF-kappaB-inducing kinase-specific siRNA using liver-targeting liposomes, Arch. Pharm. Res., 32, 1077, 10.1007/s12272-009-1714-z · DOI
  150. McMahon, 2012, Targeted gene delivery to hepatocytes with galactosylated amphiphilic cyclodextrins, J. Pharm. Pharmacol., 64, 1063, 10.1111/j.2042-7158.2012.01497.x · DOI
  151. Jain, 2013, Lactosaminated-N-succinyl chitosan nanoparticles for hepatocyte-targeted delivery of acyclovir, J. Nanoparticle Res., 16, 1
  152. Wang, 2010, Galactosylated solid lipid nanoparticles with cucurbitacin B improves the liver targetability, Drug Deliv., 17, 114, 10.3109/10717540903580176 · DOI
  153. Li, 2008, Preparation, characterization and controlled release of liver-targeting nanoparticles from the amphiphilic random copolymer, Polymer, 49, 4769, 10.1016/j.polymer.2008.09.006 · DOI
  154. Zhu, 2013, Galactosylated chitosan oligosaccharide nanoparticles for hepatocellular carcinoma cell-targeted delivery of adenosine triphosphate, Int. J. Mol. Sci., 14, 15755, 10.3390/ijms140815755 · doi:10.3390/ijms140815755
  155. Kim, 2003, Development of polymeric nanoparticulate drug delivery systems: evaluation of nanoparticles based on biotinylated poly(ethylene glycol) with sugar moiety, Int. J. Pharm., 257, 195, 10.1016/S0378-5173(03)00128-5 · DOI
  156. Jain, 2010, Development and in vitro characterization of galactosylated low molecular weight chitosan nanoparticles bearing doxorubicin, AAPS PharmSciTech, 11, 686, 10.1208/s12249-010-9422-z · doi:10.1208/s12249-010-9422-z
  157. Tao, 2014, Galactosylated biodegradable poly([varepsilon]-caprolactone-co-phosphoester) random copolymer nanoparticles for potent hepatoma-targeting delivery of doxorubicin, Polym. Chem., 5, 3443, 10.1039/c4py00024b · DOI
  158. Shen, 2011, A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy, Pharmacol. Res., 64, 410, 10.1016/j.phrs.2011.06.015 · DOI
  159. Li, 2014, High drug loading pH-sensitive pullulan-DOX conjugate nanoparticles for hepatic targeting, J. Biomed. Mater. Res. A, 102, 150, 10.1002/jbm.a.34680 · DOI
  160. Guhagarkar, 2010, Polyethylene sebacate-doxorubicin nanoparticles for hepatic targeting, Int. J. Pharm., 401, 113, 10.1016/j.ijpharm.2010.09.012 · DOI
  161. Guhagarkar, 2011, Evaluation of pullulan-functionalized doxorubicin nanoparticles for asialoglycoprotein receptor-mediated uptake in Hep G2 cell line, Cancer Nanotechnol., 2, 49, 10.1007/s12645-011-0012-x · DOI
  162. Chen, 2014, Glyco-nanoparticles with sheddable saccharide shells: a unique and potent platform for hepatoma-targeting delivery of anticancer drugs, Biomacromolecules, 15, 900, 10.1021/bm401749t · DOI
  163. Lian, 2008, Novel galactosylated SLN for hepatocyte-selective targeting of floxuridinyl diacetate, J. Drug Target., 16, 250, 10.1080/10611860801902351 · DOI
  164. Varshosaz, 2012, Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma, J. Liposome Res., 22, 224, 10.3109/08982104.2012.662653 · doi:10.3109/08982104.2012.662653
  165. Guan, 2012, Uptake and transport of a novel anticancer drug-delivery system: lactosyl-norcantharidin-associated N-trimethyl chitosan nanoparticles across intestinal Caco-2 cell monolayers, Int. J. Nanomedicine, 7, 1921
  166. Wang, 2010, Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery, Nanomedicine, 6, 371, 10.1016/j.nano.2009.07.006 · DOI
  167. Lu, 2008, The use of solid lipid nanoparticles to target a lipophilic molecule to the liver after intravenous administration to mice, Int. J. Biol. Macromol., 43, 320, 10.1016/j.ijbiomac.2008.06.006 · doi:10.1016/j.ijbiomac.2008.06.006
  168. Joshi, 2014, Receptor-mediated hepatocyte-targeted delivery of primaquine phosphate nanocarboplex using a carbohydrate ligand, Drug Deliv. Transl. Res., 4, 353, 10.1007/s13346-014-0200-4 · doi:10.1007/s13346-014-0200-4
  169. Chen, 2014, Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration, J. Control. Release, 196, 106, 10.1016/j.jconrel.2014.09.025 · DOI · Paper page
  170. Craparo, 2013, Galactosylated micelles for a ribavirin prodrug targeting to hepatocytes, Biomacromolecules, 14, 1838, 10.1021/bm4002409 · DOI
  171. Suriano, 2010, Synthesis of a family of amphiphilic glycopolymers via controlled ring-opening polymerization of functionalized cyclic carbonates and their application in drug delivery, Biomaterials, 31, 2637, 10.1016/j.biomaterials.2009.12.022 · DOI · Paper page
  172. Zhong, 2013, Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells, Biomacromolecules, 14, 3723, 10.1021/bm401098w · DOI
  173. Zou, 2014, Galactose-installed photo-crosslinked pH-sensitive degradable micelles for active targeting chemotherapy of hepatocellular carcinoma in mice, J. Control. Release, 193, 154, 10.1016/j.jconrel.2014.05.016 · DOI
  174. Wakebayashi, 2004, Lactose-conjugated polyion complex micelles incorporating plasmid DNA as a targetable gene vector system: their preparation and gene transfecting efficiency against cultured HepG2 cells, J. Control. Release, 95, 653, 10.1016/j.jconrel.2004.01.003 · DOI
  175. Oishi, 2005, Smart polyion complex micelles for targeted intracellular delivery of PEGylated antisense oligonucleotides containing acid-labile linkages, Chembiochem, 6, 718, 10.1002/cbic.200400334 · DOI
  176. Managit, 2005, Uptake characteristics of galactosylated emulsion by HepG2 hepatoma cells, Int. J. Pharm., 301, 255, 10.1016/j.ijpharm.2005.05.020 · doi:10.1016/j.ijpharm.2005.05.020
  177. Hattori, 2000, Controlled biodistribution of galactosylated liposomes and incorporated probucol in hepatocyte-selective drug targeting, J. Control. Release, 69, 369, 10.1016/S0168-3659(00)00338-2 · doi:10.1016/s0168-3659(00)00338-2
  178. Ishida, 2004, Biodistribution characteristics of galactosylated emulsions and incorporated probucol for hepatocyte-selective targeting of lipophilic drugs in mice, Pharm. Res., 21, 932, 10.1023/B:PHAM.0000029280.39882.ff · doi:10.1023/b:pham.0000029280.39882.ff
  179. Villa, 2013, Targeted doxorubicin delivery by chitosan-galactosylated modified polymer microbubbles to hepatocarcinoma cells, Colloids Surf. B: Biointerfaces, 110, 434, 10.1016/j.colsurfb.2013.04.022 · DOI
  180. Wei, 2010, Galactosylated nanocrystallites of insoluble anticancer drug for liver-targeting therapy: an in vitro evaluation, Nanomedicine (Lond.), 5, 589, 10.2217/nnm.10.27 · DOI
  181. Duan, 2011, Galactose-decorated pH-responsive nanogels for hepatoma-targeted delivery of oridonin, Biomacromolecules, 12, 4335, 10.1021/bm201270m · DOI
  182. Arima, 2010, In vitro and in vivo gene delivery mediated by lactosylated dendrimer/α-cyclodextrin conjugates (G2) into hepatocytes, J. Control. Release, 146, 106, 10.1016/j.jconrel.2010.05.030 · DOI
  183. Motoyama, 2011, In vitro gene delivery mediated by lactosylated dendrimer (generation 3, G3)/α-cyclodextrin conjugates into hepatocytes, J. Incl. Phenom. Macrocycl. Chem., 70, 333, 10.1007/s10847-010-9842-0 · doi:10.1007/s10847-010-9842-0
  184. Hayashi, 2013, Design and evaluation of polyamidoamine dendrimer conjugate with PEG, alpha-cyclodextrin and lactose as a novel hepatocyte-selective gene carrier in vitro and in vivo, J. Drug Target., 21, 487, 10.3109/1061186X.2013.769105 · DOI
  185. Medina, 2011, N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers, Biomaterials, 32, 4118, 10.1016/j.biomaterials.2010.11.068 · DOI
  186. Bhadra, 2005, Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting, Int. J. Pharm., 295, 221, 10.1016/j.ijpharm.2005.01.026 · DOI · Paper page
  187. Agrawal, 2007, Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate, Biomaterials, 28, 3349, 10.1016/j.biomaterials.2007.04.004 · DOI · Paper page
  188. Arima, 2012, Potential use of polyamidoamine dendrimer conjugates with cyclodextrins as novel carriers for siRNA, Pharmaceuticals (Basel), 5, 18
  189. Pujol, 2011, Hepatocyte targeting and intracellular copper chelation by a thiol-containing glycocyclopeptide, J. Am. Chem. Soc., 133, 286, 10.1021/ja106206z · DOI
  190. Wang, 2009, Long-term reduction of jaundice in Gunn rats by nonviral liver-targeted delivery of Sleeping Beauty transposon, Hepatology, 50, 815, 10.1002/hep.23060 · doi:10.1002/hep.23060
  191. Hohokabe, 2007, Hepatocyte-selective gene transfer by galactosylated protein/linear polyethyleneimine/plasmid DNA complexes in mice, J. Biomed. Nanotechnol., 3, 277, 10.1166/jbn.2007.034 · doi:10.1166/jbn.2007.034
  192. Kim, 2005, Synergistic effect of poly(ethylenimine) on the transfection efficiency of galactosylated chitosan/DNA complexes, J. Control. Release, 105, 354, 10.1016/j.jconrel.2005.03.024 · DOI
  193. Hwang, 1999, Preoperative assessment of residual hepatic functional reserve using 99mTc-DTPA-galactosyl-human serum albumin dynamic SPECT, J. Nucl. Med., 40, 1644
  194. Iimuro, 2010, Preoperative estimation of asialoglycoprotein receptor expression in the remnant liver from CT/99mTc-GSA SPECT fusion images correlates well with postoperative liver function parameters, J. Hepatobiliary Pancreat. Sci., 17, 673, 10.1007/s00534-010-0264-6 · doi:10.1007/s00534-010-0264-6
  195. Yumoto, 2010, Preoperative estimation of remnant hepatic function using fusion images obtained by 99mTc-labelled galactosyl-human serum albumin liver scintigraphy and computed tomography, Br. J. Surg., 97, 934, 10.1002/bjs.7025 · DOI
  196. Yoshida, 2012, Fused 99m-Tc-GSA SPECT/CT imaging for the preoperative evaluation of postoperative liver function: can the liver uptake index predict postoperative hepatic functional reserve?, Jpn. J. Radiol., 30, 255, 10.1007/s11604-011-0041-8 · DOI
  197. Kaibori, 2011, Usefulness of Tc-99m-GSA scintigraphy for liver surgery, Ann. Nucl. Med., 25, 593, 10.1007/s12149-011-0520-0 · doi:10.1007/s12149-011-0520-0
  198. Haubner, 2013, Development of (6)(8)Ga-labelled DTPA galactosyl human serum albumin for liver function imaging, Eur. J. Nucl. Med. Mol. Imaging, 40, 1245, 10.1007/s00259-013-2397-8 · doi:10.1007/s00259-013-2397-8
  199. Yoshinori, 2010, Molecular imaging contrast media for visualization of liver function, Magn. Reson. Imaging, 28, 708, 10.1016/j.mri.2010.02.003 · doi:10.1016/j.mri.2010.02.003
  200. Kamruzzaman Selim, 2007, Surface modification of magnetite nanoparticles using lactobionic acid and their interaction with hepatocytes, Biomaterials, 28, 710, 10.1016/j.biomaterials.2006.09.014 · DOI

200 of 238 shown

Cited by

See all 621

Metadata

Authors
D'Souza, A. A., & Devarajan, P. V.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2015-04
Volume
203
Pages
126-139
ISSN
0168-3659 (ISSN-L)
DOI
10.1016/j.jconrel.2015.02.022
OpenAlex
W2052108548
Cited by
621
References
3
FWCI
10.02
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Asialoglycoprotein receptor mediated hepatocyte targeting — Strategies and applications. https://app.cochat.ai/papers/10.1016/j.jconrel.2015.02.022
The paper
D'Souza, A. A., & Devarajan, P. V. (2015). Asialoglycoprotein receptor mediated hepatocyte targeting — Strategies and applications. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2015.02.022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.